View Older Stories View More Recent Stories
-
Octave Bioscience Secures $32 Million Series B Financing
-
Global Genes, Leaders in Life Sciences and Pharma, and Informa’s Biotech Showcase™ Partner to Connect Rare Disease Advocates, Investors and Companies at RARE Beyond the Square
-
Aytu BioScience (AYTU) Announces Merger Agreement with Neos Therapeutics
-
Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue¹ Specialty Pharmaceutical Company
-
Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue(1) Specialty Pharmaceutical Company
-
Deerfield Announces 2021 Cure Diversity, Innovation and Management Initiatives
-
Edgewise Therapeutics Completes $95 Million Series C Financing to Advance Clinical Development of Muscular Dystrophy Program
-
Vatica Health Appoints Experienced Executive Shannon Delage to its Board of Directors
-
Lumos Pharma to Participate in December Investor Conferences
-
Lumos Pharma to Participate in December Investor Conferences
-
Syngene and Deerfield Discovery and Development (3DC) sign 5-year strategic collaboration
-
Form 13F-HR DEERFIELD MANAGEMENT For: Sep 30
-
Nuvo Pharmaceuticals® Announces Third Quarter 2020 Results
-
Springtide Announces $18.1M in Funding to Accelerate Centers for Autism Care
-
Bridge Medicines Announces Additional Funding of $10 Million from Inside Investors
-
Lumos Pharma Announces the Initiation of Phase 2b OraGrowtH210 Trial and Reports Third Quarter 2020 Financial Results
-
Lumos Pharma Announces the Initiation of Phase 2b OraGrowtH210 Trial and Reports Third Quarter 2020 Financial Results
-
Boston Children’s Hospital and Deerfield Join Forces to Accelerate the Development of Novel Therapies to Patients
-
Blade Therapeutics to Present at the 2020 Stifel Virtual Healthcare Conference
-
Lumos Pharma to Participate in November Investor Conferences
-
Lumos Pharma to Participate in November Investor Conferences
-
Ready Launches Virtual Mental Health Services as Part of Unique At-Home Care Model
-
Lumos Pharma to Report Third Quarter 2020 Financial Results and Host a Conference Call on November 10, 2020
-
Lumos Pharma to Report Third Quarter 2020 Financial Results and Host a Conference Call on November 10, 2020
-
Dracen Pharmaceutical's DRP-104 Granted U.S. FDA Fast Track Designation for the treatment of Non-Small Cell Lung Cancer
-
Miami Residents to Receive COVID-19 Testing and Medical Care from On-Demand Healthcare Service Ready
-
The New York Academy Of Medicine Welcomes New Board Chair Dr. Wayne Riley, President Of SUNY Downstate
-
InCarda Therapeutics Raises $30 Million Through First Close of Series C Equity Financing
-
Nuvation Bio and Panacea Announce Business Combination Agreement, Creating a Publicly Listed Leader in Oncology Drug Development
-
Nuo Therapeutics Announces Recapitalization and Exchange Agreement that Simplifies Capital Structure
-
Curation Health Announces Series A Financing from Deerfield Management Company and WindRose Health Investors
-
Olema Oncology Raises $85 Million in Series C Financing to Advance Clinical Development of OP-1250 in Breast Cancer
-
Dracen Pharmaceuticals Announces the Initiation of First-in-human Study of DRP-104 in Adult Patients With Advanced Solid Tumors
-
V-Wave Completes Financing of Up to $98M from Syndicate of Leading Global Healthcare Investors
-
Bridge Medicines Adds Small Molecule Inhibitors of Activated Factor XII to Pipeline
-
On-demand Healthcare Service, Ready, Raises $54 Million in Series C Financing
-
Element Science Names Zubin J. Eapen, MD as Chief Medical Officer
-
Blade Therapeutics Reaches Enrollment Goal for Phase 2 Study of Lead Investigational Therapy BLD-2660 in Treating Patients With COVID-19 Pneumonia
-
Deerfield Healthcare Technology Acquisitions Corp. Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing on or about September 14, 2020
-
BioNJ Announces Lineup for Virtual BioPartnering Conference
-
Lumos Pharma to Participate in Upcoming Investor Conferences
-
Lumos Pharma to Participate in Upcoming Investor Conferences
-
Oxford Finance Provides Credit Facility to Brain Injury Rehab Provider ReMed Holdings, LLC
-
Overdose Crisis Endures, Yet Few People Receive Existing Effective Treatment
-
Form 13F-HR DEERFIELD MANAGEMENT For: Jun 30
-
Lumos Pharma Reports Second Quarter 2020 Results and Provides Update on Clinical and Corporate Activities
-
Lumos Pharma Reports Second Quarter 2020 Results and Provides Update on Clinical and Corporate Activities
-
Blade Therapeutics Updates Enrollment Progress for Phase 2 Study of Lead Investigational Therapy BLD-2660 in Treating Patients with COVID-19 Pneumonia
-
Larimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results
-
Larimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results

